Opinion|Videos|October 16, 2024
Treatment Breaks and Rescue Treatments in Atopic Dermatitis
Key Takeaways
- Patients frequently discuss treatment breaks, influenced by individual treatment responses and personal circumstances.
- Monitoring during treatment breaks involves regular follow-ups to assess disease activity and manage potential flares.
Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Given the chronic condition of atopic dermatitis, patients may choose or need to stop treatment during their treatment journey. How often do patients bring up the need for a treatment break?
- How do you monitor patients during this period?
- How do you educate and counsel patients about treatment breaks and rescue treatments?
- Which patient is/is not a good candidate for it?
Advertisement
Related to this article
For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
4
FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE
5